In addition, 10-year follow-up results of the Austrian Breast and Colorectal Cancer Study Group 8A trial suggested patients with hormonal receptor-positive, tumor sizes up to 3 cm, T1 or T2 (early) tumor stages; negative lymph nodes BC treated with BCS and consecutive ET with whole breast RT had a better local control (97.5% vs 92.4%, p = 0.004) and disease-free survival (94.5% vs 88.4%, p = 0.0156) compared with ET alone. This evidence concerns the gene NR4A1 and breast cancer.